EPRI today launched a new global consortium?the Open Power AI Consortium?to drive the development and deployment of an open AI model tailored for the power sector, accelerating AI adoption to reduce ...

The only other drug currently in its pipeline is RVT-104, a combination of glycopyrrolate and high dose rivastigmine, Novartis' off-patent Alzheimer's drug Exelon.

Desjardins Securities analyst Gary Ho sees TerraVest Industries Inc. ’s ( N/A ) US$546-million acquisition of EnTrans International as “transformative” and puts “an under-levered balance sheet to work ...

Tariffs and geopolitical uncertainty are enough to turn even the most bullish investors into bears. Protect your portfolio ...

Reports record-high revenues since inceptionMONTREAL, March 20, 2025 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc. (TSX: GUD) ("Knight" or “the Company”), a pan-American (ex-US) specialty ...

MONTREAL, March 20, 2025 (GLOBE NEWSWIRE) — Knight Therapeutics Inc. (TSX: GUD) (“Knight” or “the Company”), a pan-American (ex-US) specialty pharmaceutical ...

MONTREAL, March 20, 2025 (GLOBE NEWSWIRE) — Knight Therapeutics Inc. (TSX: GUD) (“Knight” or “the Company”), a pan-American (ex-US) specialty pharmaceutical company, today reported financial results ...

the timing of the entry of generic competition, the expected results of tenders, among other variables. Knight Therapeutics Inc., headquartered in Montreal, Canada, is a specialty pharmaceutical ...

Organizers said they hope to empower seniors to improve balance, alleviate pain and stiffness and increase confidence.